SG Americas Securities
VYGR icon

SG Americas Securities’s Voyager Therapeutics VYGR Stock Holding History

SG Americas Securities’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,700
Closed -$4K – 3276
2021
Q1 		$4K Buy
+40,700
New +$278K ﹤0.01% 3224

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's VYGR Position: Q2 2025 in Review

SG Americas Securities sold out of Voyager Therapeutics (VYGR) in Q2 2025, closing a stake of 16,568 shares — an estimated $56K sold.

SG Americas Securities first reported a position in VYGR in Q3 2016 and held it in 16 quarters. The position peaked at $1.49M in Q2 2019. 112 funds tracked by Wall St. Rank hold VYGR as of Q2 2025.

  • SG Americas Securities reported no remaining Voyager Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 16,568 Voyager Therapeutics shares in Q2 2025, an estimated $56K.
  • SG Americas Securities first reported a position in Voyager Therapeutics in Q3 2016 and held it in 16 quarters.
  • SG Americas Securities's Voyager Therapeutics position peaked at $1.49M in Q2 2019.
  • 112 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.